Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or...
Reexamination Certificate
1999-04-30
2002-04-23
Caputa, Anthony C. (Department: 1642)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
C435S007100, C435S006120, C436S064000
Reexamination Certificate
active
06376169
ABSTRACT:
BACKGROUND OF THE INVENTION
Many pathological conditions such as preeclampsia, peripheral vascular disease, erectile dysfunction, cancers, renal failure, heart disease, and stroke are often associated with alterations in the normal vascular condition of the affected tissues and/or systems. While the change from normal vascular condition may arise through natural physiological processes, it may also be induced transiently by perturbations such as surgical procedures, and by the presence of exogenous agents within the body. The change in vascular condition can result in a reduction in blood flow to the associated organ or system, rendering that organ or system hypoxic.
SUMMARY OF THE INVENTION
This invention relates to methods for diagnosing vascular conditions, and to methods for detecting hypoxia or endothelial dysfunction in an individual. In one aspect, the invention relates to a method for diagnosing a vascular condition leading to a hypoxic state. The methods of the invention comprise the steps of:
i) measuring the level of at least one substance in at least one biological sample, said substance having a level which is affected by a vascular condition associated with a reduction in blood flow, hypoxia or endothelial dysfunction; and
ii) comparing the level of the substance in said biological sample with a standard to determine the extent of said vascular condition associated with a reduction in blood flow, hypoxia or endothelial dysfunction.
According to a further aspect of the method of the invention, a corresponding measure of the level of at least one substance is performed in at least one different biological sample, said different biological sample being unaffected by a vascular condition associated with a reduction in blood flow, hypoxia or endothelial dysfunction. The substance may be selected from the group consisting of genes, gene products, metabolites, metabolic by-products, hormones, and exogenous agents.
In a particular embodiment, the invention is a method of diagnosing a vascular condition associated with a reduction in the flow of blood within an anatomical site of an individual and the substance measured is a product of the RTP/Drg1 gene.
In additional embodiments, the invention is a method of detecting hypoxia or endothelial dysfunction in an individual and the substance measured is a product of a gene selected from the group consisting of RTP/Drg1, uPAR and PAI-1. In another embodiment, the invention is a method of detecting hypoxia or endothelial dysfunction in an individual and the substance measured is an arginine metabolite, such as L-NMMA or ADMA.
In another embodiment, the invention is a method of diagnosing a vascular condition in an individual, comprising the steps of:
i) measuring the quantity of at least two substances chosen from the group consisting of a product of the RTP/Grp1 gene, a product of the uPAR gene, a product of the PAI-1 gene and an arginine metabolite, in at least one biological sample obtained from said individual; and
ii) comparing the measured quantity of said substances to a standard value for the quantity of said substances in a normal biological sample; wherein
an increase in the measured quantity of at least one of said substances relative to the standard value is indicative of said vascular condition. The method of this embodiment can further comprise an indirect assay, such as evaluating the in vitro invasiveness of cells isolated from said individual.
In a further embodiment, the invention is a method of assessing an individual's risk for a vascular condition associated with a reduction in the flow of blood, comprising
i) measuring the quantity of a product of the RTP/Drg1 gene in at least one biological sample; and
ii) comparing the quantity of said product of the RTP/Drg1 gene in said biological sample with a standard; wherein
an increase in the measured quantity of said RTP/Drg1 gene product relative to the standard value is indicative of risk for said vascular condition, and said risk correlates with the degree to which said RTP/Drg1 gene product is elevated.
The invention also relates to a method of diagnosing a vascular condition in an individual. The method comprises detecting at least one endocrine disrupter in at least one biological sample obtained from an individual, wherein the presence of said endocrine disrupter is indicative of said vascular condition. In one embodiment, the endocrine disrupter p,p-DDE is detected to diagnose erectile dysfunction.
REFERENCES:
patent: 4968603 (1990-11-01), Slamon et al.
patent: 5039608 (1991-08-01), Goldstein et al.
patent: 5688649 (1997-11-01), Croce et al.
patent: 5688658 (1997-11-01), Diamandis
patent: 5700447 (1997-12-01), Bucala et al.
patent: 5733790 (1998-03-01), Potter et al.
patent: 5804392 (1998-09-01), Esmon et al.
patent: 5814462 (1998-09-01), Weinberger
patent: 5912135 (1999-06-01), Luderer et al.
Malinow, et al, 1989,; Circulation 1180-1188.*
Alberts et al. (Molecular Biology of the Cell, 3rd edition, 1994, p. 465).*
Freshney (Culture of Animal Cells, A Manual of Basic Techniques, Alan R. Liss, Inc., 1983, New York, p4).*
Dermer (Bio/Technology, 1994, 12:320).*
Tockman et al. (Cancer Res., 1992, 52:2711s-2718s).*
Vallance, P., et al., “Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure,”The Lancet, 339: pp. 572-75 (Mar. 1992).
Roberts, J. M., et al., “Pre-eclampsia: more than pregnancy-induced hypertension,”The Lancet, 341: pp. 1447-1451 (Jun. 1993).
Del Vecchio, S., et al., “Human Urolkinase Receptor Concentration in Malignant and Benign Breast Tumors by in Vitro Quantitative Autoradiography: Comparison with Urokinase Levels,”Cancer Research, 53: pp. 3198-3206 (Jul. 1993).
Fickling, S. A., et al., “Plasma concentrations of endogenous inhibitor of nitric oxide synthesis in normal pregnancy and pre-eclampsia,”The Lancet, 342: pp. 242-243 (Jul. 1993).
Lord, E. M., et al., “Detection o Hypoxic Cells by Monoclonal Antibody Recognizing 2-Nitroimidazole Adducts,”Cancer Research, 53: pp. 5721-5726 (Dec. 1993).
Klokker, M., et al., “Influence of in vivo hypobaric hypoxia on function of lymphocytes, neutrocytes, natural killer cells, and cytokines,”J. Appl. Physiol., 74(3): pp. 1100-1106 (1993).
Zhou, Y., et al., “Increased depth of trophoblast invasion after chronic constriction of the lower aorta in rhesus monkeys,”Am. J. Obstet. Gynecol., 169: pp. 224-229 (1993).
Pahl, H. L., et al., “Oxygen and the Control of Gene Expression,”BioEssays, 16(7): pp. 497-502 (Jul. 1994).
Foekens, J. A., et al., “Plasminogen Activator Inhibitor-1 and Prognosis in Primary Breast Cancer,”Journal of Clinical Oncology., 12(8): pp. 1648-1658 (Aug. 1994).
Pedersen, H., et al., “Prognostic Impact of Urokinase, Urokinase Receptor, and Type 1 Plasminogen Activator Inhibitor in Squamous and Large Cell Lung Cancer Tissue,”Cancer Research, 54: pp. 4671-4675 (Sep. 1994).
Sawa, H., et al., “Increased Intramural Expression of Plasminogen Activator Inhibitor Type 1 After Balloon Injury: A Potential Progenitor of Restenosis,”Journal of the American College of Cardiology, 24(7): pp. 1742-1748 (Dec. 1994).
Arnman, V., et al., “Expression of Plasminogen Activator Inhibitor-1 mRNA in Healthy, Atherosclerotic and Thrombotic Human Arteries and Veins,”Thrombosis Research, 76(5): pp. 487-499 (1994).
Salat, C., et al., “Parameters of the fibrinolytic system in patients undergoing BMT: elevation of PAI-1 in veno-occlusive disease,”Bone Marrow Transplantation, 14: pp. 747-750 (1994).
Shweiki, D., et al., “Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: Implications for tumor angiogenesis,”Proc. Natl. Acad. Sci. U.S.A., 92: pp. 768-772 (Jan. 1995).
Grøndahl-Hansen, J., et al., “Prognostic Significance of the Receptor for Urokinase Plasminogen Activator in Breast Cancer,”Clinical Cancer Research, 1: pp. 1079-1087 (Oct. 1995).
Rutherford, R. A. D., et al., “Nitric oxide synthase in human placenta andumbilical cord from normal, intrauterine growth-retarded and pre-eclamptic pregnancies,”British Jo
Adams Michael A.
Brien Susan E.
Graham Charles H.
Heaton Jeremy P. W.
Caputa Anthony C.
Licata & Tyrrell P.C.
Nickol Gary B
Queen's University at Kingston
LandOfFree
Method for diagnosing a vascular condition does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for diagnosing a vascular condition, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for diagnosing a vascular condition will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2872151